Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure

Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

Lenacapavir becomes the first and only twice-yearly option for HIV prevention.

A Welsh health board will not commission a pilot to deliver HIV pre-exposure prophylaxis (PrEP) through community pharmacies, The Pharmaceutical Journal has learned. A pilot scheme to deliver PrEP…

According to the U.S. Centers for Disease Control and Prevention (CDC) and other sources, there are approximately 1.2 million people living with HIV in the United States, and another 1.2 to 2.2 millio...